Business News

Amgen And The Institute For Protein Design at University of Washington Partner to Test New Technologies and Create Protein-Building Approaches for New Medicines

THOUSAND OAKS, Calif. and SEATTLE, June 19, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) and the University of Washington’s Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health, today announced a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building …

Read More »

Gilead Enters $2.4 Billion Deal with Nurix for Development of Innovative Targeted Protein Degradation Drugs

FOSTER CITY, Calif. & SAN FRANCISCO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients …

Read More »

Catalent to Buy Bristol-Myers Squibb’s Manufacturing Facility in Italy

NEW YORK & SOMERSET, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Catalent, Inc. (NYSE: CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies,development and manufacturing solutions for drugs, …

Read More »

Ultragenyx and Arcturus Expand Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

NOVATO, Calif. and SAN DIEGO, June 19, 2019 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a leading messenger RNA medicines company, today announced that they …

Read More »

Retrophin Enters R&D Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome

SAN DIEGO, June 18, 2019 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient advocacy foundation Alagille Syndrome Alliance (ALGSA) to collaborate …

Read More »

Sanofi and Google Partner to Use Data Technologies for Innovations

PARIS – June 18, 2019 – Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies. “We stand on the forefront of a new age for biology and …

Read More »

Voyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update

CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced a restructuring of its gene therapy relationship with Sanofi Genzyme. Under the terms of the agreement, Voyager gains worldwide rights to …

Read More »

Pfizer Expands Cancer Portfolio through $11.4 Billion Acquisition of Array BioPharma

NEW YORK & BOULDER, Colo.–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to …

Read More »

OncoSec Partners with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy, TAVO-PLUS and APOLLO Electroporation Generator

SAN DIEGO, and PENNINGTON, N.J., June 17, 2019 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has initiated a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park’s intravital microscopy (IVM) and OncoSec’s proprietary …

Read More »

BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab from Celgene

CAMBRIDGE, Mass. and BEIJING, China, June 17, 2019 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it has entered into a mutual agreement with Celgene Corporation to …

Read More »